Navigation Links
Duska Therapeutics to Present at Noble Financial Equity 'M.A.D. MAX' Conference on Tuesday, August 19th at 1:30 p.m. PDT
Date:8/19/2008

LA JOLLA, Calif., Aug. 19 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska") announced today that its CEO, James S. Kuo, M.D., M.B.A. will present at the fourth annual Noble Financial Equity Conference on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in Las Vegas, Nevada. Duska's presentation is scheduled for 1:30 p.m. PDT. Dr. Kuo will also be available for one-on-one meetings throughout the day.

The presentation with streaming video and PowerPoint will be webcast live and archived on Noble Financial's conference website at http://www.noblemadmax.com. Participants should register at least 10 minutes prior to the start of the presentation to ensure timely access.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Duska is developing a portfolio of investigational medicines, two of which are in late stages of clinical testing. Duska's ATPace(TM) is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that Duska will present at the fourth annual Noble Financial Equity Conference on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in Las Vegas, Nevada. Duska's presentation is scheduled for 1:30 p.m. PDT. Dr. Kuo will also be available for one-on-one meetings throughout the day. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
2. Duska Therapeutics Obtains Standard & Poors Listing
3. Arno Therapeutics Announces Second Quarter 2008 Financial Results
4. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
5. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
6. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
9. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
10. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model Aeronautics ... leading maker of unmanned aircraft systems (UAS), are launching a joint program to ... effectively, and support educational outreach efforts. , AMA and DJI will collaborate on ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... Avomeen & ... The event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann ... MichBio member organization. They provide an opportunity to interact with peers, make new connections ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
(Date:2/16/2017)... 16, 2017   Capricor Therapeutics, Inc. ... company developing first-in-class biological therapies for cardiac and ... elected to terminate its license agreement with the ... including Cenderitide. "Our decision to return ... prioritize our efforts to advance our core cell ...
Breaking Biology Technology:
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
Breaking Biology News(10 mins):